Hong Kong · Delayed Price · Currency is HKD Metis TechBio Statistics
Total Valuation
Metis TechBio has a market cap or net worth of HKD 21.73 billion. The enterprise value is 18.61 billion.
| Market Cap | 21.73B |
| Enterprise Value | 18.61B |
Important Dates
The last earnings date was Tuesday, August 25, 2026.
| Earnings Date | Aug 25, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Metis TechBio has 1.18 billion shares outstanding. The number of shares has increased by 13.53% in one year.
| Current Share Class | 1.08B |
| Shares Outstanding | 1.18B |
| Shares Change (YoY) | +13.53% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 23.22% |
| Owned by Institutions (%) | 12.16% |
| Float | 553.80M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 72.90 |
| PB Ratio | 6.24 |
| P/TBV Ratio | 6.24 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 62.46 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 17.68, with a Debt / Equity ratio of 0.06.
| Current Ratio | 17.68 |
| Quick Ratio | 17.55 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.86 |
| Interest Coverage | -10.83 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -10.78% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 1.99M |
| Profits Per Employee | -2.72M |
| Employee Count | 150 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Metis TechBio has paid 3.82 million in taxes.
| Income Tax | 3.82M |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 12.43 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 70.61 |
| Average Volume (20 Days) | 6,852,646 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Metis TechBio had revenue of HKD 298.03 million and -408.16 million in losses. Loss per share was -0.46.
| Revenue | 298.03M |
| Gross Profit | 294.72M |
| Operating Income | -391.22M |
| Pretax Income | -404.34M |
| Net Income | -408.16M |
| EBITDA | -354.96M |
| EBIT | -391.22M |
| Loss Per Share | -0.46 |
Balance Sheet
The company has 3.32 billion in cash and 206.98 million in debt, with a net cash position of 3.11 billion or 2.63 per share.
| Cash & Cash Equivalents | 3.32B |
| Total Debt | 206.98M |
| Net Cash | 3.11B |
| Net Cash Per Share | 2.63 |
| Equity (Book Value) | 3.48B |
| Book Value Per Share | 2.95 |
| Working Capital | 3.30B |
Cash Flow
In the last 12 months, operating cash flow was -216.44 million and capital expenditures -24.67 million, giving a free cash flow of -241.10 million.
| Operating Cash Flow | -216.44M |
| Capital Expenditures | -24.67M |
| Depreciation & Amortization | 36.71M |
| Net Borrowing | 42.12M |
| Free Cash Flow | -241.10M |
| FCF Per Share | -0.20 |
Margins
Gross margin is 98.89%, with operating and profit margins of -131.27% and -136.95%.
| Gross Margin | 98.89% |
| Operating Margin | -131.27% |
| Pretax Margin | -135.67% |
| Profit Margin | -136.95% |
| EBITDA Margin | -119.10% |
| EBIT Margin | -131.27% |
| FCF Margin | n/a |
Dividends & Yields
Metis TechBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.53% |
| Shareholder Yield | -13.53% |
| Earnings Yield | -1.88% |
| FCF Yield | -1.11% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for Metis TechBio is 24.64, which is 44.94% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 24.64 |
| Price Target Difference | 44.94% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 96.94% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Metis TechBio has an Altman Z-Score of 32.58 and a Piotroski F-Score of 3.
| Altman Z-Score | 32.58 |
| Piotroski F-Score | 3 |